Anti-Platelet Agents has 14 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Eptifibatide, Mitapivat, Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Alafenamide. Patients taking Anti-Platelet Agents should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 14
- Contraindicated
- 2
- Major
- 2
- Moderate
- 9
Contraindicated (2)
- Anti-Platelet Agents + Eptifibatide— Concomitant treatment with other GP IIb/IIIa inhibitors should be avoided.
- Anti-Platelet Agents + Mitapivat— PYRUKYND may affect P-gp substrates with narrow therapeutic index. Avoid concomitant use.
Major (2)
- Anti-Platelet Agents + Emtricitabine, Rilpivirine Hydrochloride, And Tenofovir Alafenamide— Drugs that induce P-gp activity may decrease TAF absorption, resulting in decreased plasma concentration and loss of the…
- Anti-Platelet Agents + Pentoxifylline— Bleeding has been reported in patients treated with pentoxifylline with or without concomitant platelet aggregation inhi…
Moderate (9)
- Anti-Platelet Agents + Apalutamide— Apalutamide induces P-glycoprotein and decreases exposure of P-gp substrates, which may decrease their effectiveness. Co…
- Anti-Platelet Agents + Dalteparin Sodium— Use of FRAGMIN with platelet inhibitors may increase the risk of bleeding.
- Anti-Platelet Agents + Eliglustat— Eliglustat may increase concentrations of P-glycoprotein substrates, increasing toxicity risk. Monitor therapeutic conce…
- Anti-Platelet Agents + Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide— Cobicistat inhibits P-gp, which may increase plasma concentrations of P-gp substrates.
- Anti-Platelet Agents + Neratinib— NERLYNX increases concentrations of P-gp substrates, which may increase risk of adverse reactions. Monitor for adverse r…
- Anti-Platelet Agents + Omega-3-Acid Ethyl Esters— Omega-3-acid ethyl esters may prolong bleeding time. Patients receiving both should be monitored periodically.
- Anti-Platelet Agents + Omega-3-Acid Ethyl Esters Capsules— Omega-3-acid ethyl esters may prolong bleeding time. Patients taking concomitant anti-platelet agents should be monitore…
- Anti-Platelet Agents + Osimertinib— Osimertinib increases substrate exposure, potentially increasing toxicity risk. Monitor for adverse reactions of the sub…
- Anti-Platelet Agents + Selumetinib— KOSELUGO capsules contain vitamin E; concomitant use may increase bleeding risk. Monitor for bleeding.